Pirlog CF - Search Results

1

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer-A Review of the Literature.

Stanciu IM, Parosanu AI, Orlov-Slavu C, Iaciu IC, Popa AM, Olaru CM, Pirlog CF, Vrabie RC, Nitipir C. Stanciu IM, et al. Among authors: pirlog cf. Diagnostics (Basel). 2023 Mar 5;13(5):987. doi: 10.3390/diagnostics13050987. Diagnostics (Basel). 2023. PMID: 36900131 Free PMC article. Review.

2

Infection and reinfection with SARS-CoV-2 in cancer patients: A cohort study.

Nitipir C, Parosanu AI, Olaru M, Popa AM, Pirlog C, Iaciu C, Vrabie R, Stanciu MI, Oprescu-Macovei A, Bumbacea D, Negrei C, Orlov-Slavu C. Nitipir C, et al. Exp Ther Med. 2022 Jun;23(6):399. doi: 10.3892/etm.2022.11326. Epub 2022 Apr 15. Exp Ther Med. 2022. PMID: 35619634 Free PMC article.

3

Use of Immune Checkpoint Inhibitors in Elderly Patients With Chronic Kidney Disease and Renal Cell Carcinoma Metastasis of the Parotid Gland: Case Report and Review of the Literature.

Parosanu A, Orlov Slavu C, Pirlog C, Stanciu IM, Nitipir C. Parosanu A, et al. Cureus. 2022 Sep 6;14(9):e28868. doi: 10.7759/cureus.28868. eCollection 2022 Sep. Cureus. 2022. PMID: 36225438 Free PMC article.

4

Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy.

Parosanu A, Stanciu IM, Pirlog C, Orlov Slavu C, Cotan H, Iaciu C, Popa AM, Olaru M, Moldoveanu O, Catalin B, Nitipir C. Parosanu A, et al. Cureus. 2022 Oct 29;14(10):e30821. doi: 10.7759/cureus.30821. eCollection 2022 Oct. Cureus. 2022. PMID: 36451642 Free PMC article. Review.

5

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma.

Parosanu AI, Pirlog CF, Slavu CO, Stanciu IM, Cotan HT, Vrabie RC, Popa AM, Olaru M, Iaciu C, Bratu LI, Baicoianu IF, Moldoveanu O, Baston C, Nițipir C. Parosanu AI, et al. Among authors: pirlog cf. Curr Oncol. 2023 Feb 17;30(2):2457-2464. doi: 10.3390/curroncol30020187. Curr Oncol. 2023. PMID: 36826148 Free PMC article.

6

Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review.

Stanciu IM, Pirlog CF, Anghel AW, Parosanu AI, Olaru CM, Orlov-Slavu C, Iaciu IC, Popa AM, Vrabie RC, Nitipir C. Stanciu IM, et al. Among authors: pirlog cf. Medicina (Kaunas). 2023 Apr 1;59(4):696. doi: 10.3390/medicina59040696. Medicina (Kaunas). 2023. PMID: 37109654 Free PMC article. Review.

7

Restricted Mean Survival Time-Can It Be a New Tool in Assessing the Survival of Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors?

Pîrlog CF, Costache R, Paroșanu AI, Slavu CO, Olaru M, Popa AM, Iaciu C, Niță I, Moțatu P, Cotan HT, Oprița AV, Costache D, Manolescu LSC, Nițipir C. Pîrlog CF, et al. Diagnostics (Basel). 2023 May 29;13(11):1892. doi: 10.3390/diagnostics13111892. Diagnostics (Basel). 2023. PMID: 37296744 Free PMC article.

8

Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors-A Systematic Review of the Literature.

Pîrlog CF, Paroșanu AI, Slavu CO, Olaru M, Popa AM, Iaciu C, Niță I, Moțatu P, Horia C, Manolescu LSC, Nițipir C. Pîrlog CF, et al. Curr Oncol. 2022 Dec 2;29(12):9428-9436. doi: 10.3390/curroncol29120741. Curr Oncol. 2022. PMID: 36547155 Free PMC article. Review.

9

Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer.

Pirlog CF, Cotan HT, Parosanu A, Orlov Slavu C, Popa AM, Iaciu C, Olaru M, Oprita AV, Nita I, Nitipir C. Pirlog CF, et al. Cureus. 2022 Jul 14;14(7):e26843. doi: 10.7759/cureus.26843. eCollection 2022 Jul. Cureus. 2022. PMID: 35974841 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9 results

Search Page